Stifel Remains Bullish on Tango Therapeutics (TNGX)
Key takeaways
- Stifel Remains Bullish on Tango Therapeutics (TNGX) Noor Ul Ain Rehman Mon, May 11, 2026 at 6:13 AM GMT+7 2 min read TNGX SF GILD Tango Therapeutics, Inc.
- (NASDAQ:TNGX) reported in its fiscal Q4 and full year 2025 results that it held $343.1 million in cash, cash equivalents, and marketable securities, which it expects to fund operations into 2028.
- (NASDAQ:TNGX) is a clinical-stage biotechnology company that discovers and delivers precision cancer medicines.
Stifel Remains Bullish on Tango Therapeutics (TNGX) Noor Ul Ain Rehman Mon, May 11, 2026 at 6:13 AM GMT+7 2 min read TNGX SF GILD Tango Therapeutics, Inc. (NASDAQ:TNGX) is one of the best performing healthcare stocks so far in 2026. Stifel lifted the price target on Tango Therapeutics, Inc. (NASDAQ:TNGX) to $40 from $24 on April 27, maintaining a Buy rating on the shares. The firm cited elevated conviction for the PRMT5 inhibitor + RAS(ON) inhibitor synergy in pancreatic ductal adenocarcinoma.
For additional context, Tango Therapeutics, Inc. (NASDAQ:TNGX) reported in its fiscal Q4 and full year 2025 results that it held $343.1 million in cash, cash equivalents, and marketable securities, which it expects to fund operations into 2028. It further reported that collaboration revenue for the quarter was $0 compared to $5.4 million for the same period in 2024, and $62.4 million for the full year, compared to $30.0 million for the prior year period.
It added that all of the remaining deferred revenue under the Gilead collaboration was recognized as collaboration revenue during fiscal Q3 2025 as a result of the truncation of the collaboration agreement, which concluded all research activities.